Drug Type Small molecule drug |
Synonyms Etazolate hydrochloride (USAN), EHT 202, EHT-0202 + [2] |
Target |
Mechanism GABAA receptor modulators(Gamma-aminobutyric acid A receptor modulators), PDE4 inhibitors(Phosphodieterase 4 inhibitors), α-secretases stimulants(Alpha secretases stimulants) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC14H19N5O2 |
InChIKeyOPQRBXUBWHDHPQ-UHFFFAOYSA-N |
CAS Registry51022-77-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 2 | FR | 01 Apr 2008 | |
Cognition Disorders | Phase 2 | - | - | |
Cognition Disorders | Phase 2 | - | - | |
Parkinson Disease | Phase 1 | FR | - | |
Retinal Diseases | Phase 1 | FR | - | |
Dementia, Vascular | Preclinical | FR | - |